Degarelix acetate powder and solvent for solution for injection IP 80mg Taj Pharma
Degarelix acetate 80 Injection is used in the treatment of advanced prostate cancer. It works by lowering the amount of testosterone produced in the body and restricts the growth of a cancer cell.
Degarelix acetate 80 Injection is given as an injection under the skin only under the supervision of a doctor.? Do not try to self inject the medicine as it might enhance the chances of an accident or get injected into the veins. The dose and how often you take it depends on what you are taking it for. Your doctor will decide how much you need to improve your symptoms. You should take this medicine for as long as it is prescribed for you.
The most common side effects of this medicine include Injection site reactions (pain, swelling, redness), weight gain, hot flashes, increased liver enzyme, and low sexual desire. If these bother you or appear serious, let your doctor know. There may be ways of reducing or preventing them. If you notice dizziness or trouble sleeping, then better to avoid driving or machinery work.
Before taking this medicine, tell your doctor if you have ever had heart disease, or diabetes or liver disease. Your doctor should also know about all other medicines you are taking as many of these may make this medicine less effective or change the way it works. Tell your doctor if you are pregnant or breastfeeding. Your doctor may check for prostate specific antigen (PSA) level in your blood, to know treatment is working or not.
USES OF DEGARELIX ACETATE INJECTION
- Prostate cancer
SIDE EFFECTS OF DEGARELIX ACETATE INJECTION
- Injection site reactions (pain, swelling, redness)
- Weight gain
- Hot flashes
- Increased liver enzymes
- Low sexual desire
- Erectile dysfunction
HOW TO USE DEGARELIX ACETATE INJECTION
Your doctor or nurse will give you this medicine. Kindly do not self administer.
HOW DEGARELIX ACETATE INJECTION WORKS
Degarelix acetate 80 Injection lowers the amount of testosterone (a male hormone) produced by the body. This may slow or stop the spread and growth of prostate cancer cells that need testosterone to grow.
Caution is advised when consuming alcohol with Degarelix acetate 80 Injection. Please consult your doctor.
Degarelix acetate 80 Injection is highly unsafe to use during pregnancy. Seek your doctor’s advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
CONSULT YOUR DOCTOR
Information regarding the use of Degarelix acetate 80 Injection during breastfeeding is not available. Please consult your doctor.
Degarelix acetate 80 Injection may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
CONSULT YOUR DOCTOR
There is limited information available on the use of Degarelix acetate 80 Injection in patients with kidney disease. Please consult your doctor.
A cautious use of Degarelix acetate 80 Injection is advised in patients with severe kidney disease.
Degarelix acetate 80 Injection should be used with caution in patients with severe liver disease. Dose adjustment of Degarelix acetate 80 Injection may be needed. Please consult your doctor.
No dose adjustment is recommended for patients with mild to moderate liver disease. Regular monitoring of testosterone levels is advised.
WHAT IF YOU FORGET TO TAKE DEGARELIX ACETATE INJECTION?
If you miss a dose of Degarelix acetate 80 Injection, please consult your doctor.
Degarelix acetate powder and solvent for solution for injection IP 80mg Taj Pharma
1. NAME OF THE MEDICINAL PRODUCT
a) Degarelix acetate powder and solvent for solution for injection IP 80mg Taj Pharma
b) Degarelix acetate powder and solvent for solution for injection IP 120mg Taj Pharma
2.QUALITATIVE AND QUANTITATIVE COMPOSITION??????????????????????????????
a) Each vial contains 80mg degarelix IP (as acetate).
After reconstitution, each ml of solution contains 20 mg of degarelix.
For the full list of excipients, see section 6.1.
Powder and solvent for solution for injection.
Powder: White to off-white powder
Solvent: Clear, colourless solution
4.1 Therapeutic indications
Degarelix acetate is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer.
4.2 Posology and method of administration
|Starting dose||Maintenance dose ? monthly administration|
|240 mg administered as two consecutive subcutaneous injections of 120 mg each||80 mg administered as one subcutaneous injection|
The first maintenance dose should be given one month after the starting dose.
The therapeutic effect of degarelix should be monitored by clinical parameters and prostate specific antigen (PSA) serum levels. Clinical studies have shown that testosterone (T) suppression occurs immediately after administration of the starting dose with 96% of the patients having serum testosterone levels corresponding to medical castration (T?0.5 ng/ml) after three days and 100% after one month. Long term treatment with the maintenance dose up to 1 year shows that 97% of the patients have sustained suppressed testosterone levels (T?0.5 ng/ml).
In case the patient’s clinical response appears to be sub-optimal, it should be confirmed that serum testosterone levels are remaining sufficiently suppressed.
Since degarelix does not induce a testosterone surge it is not necessary to add an anti-androgen as surge protection at initiation of therapy.
Elderly, hepatically or renally impaired patients:
There is no need to adjust the dose for the elderly or in patients with mild or moderate liver or kidney function impairment (see section 5.2). Patients with severe liver or kidney impairment have not been studied and caution is therefore warranted (see section 4.4).
There is no relevant use of Degarelix acetate in children and adolescents in the treatment of adult male patients with advanced hormone-dependent prostate cancer.
Method of administration
Degarelix acetate must be reconstituted prior to administration. For instructions on reconstitution and administration, please see section 6.6.
Degarelix acetate is for subcutaneous use ONLY, not to be administered intravenously. Intramuscular administration is not recommended as it has not been studied.
Degarelix acetate is administered as a subcutaneous injection in the abdominal region. The injection site should vary periodically. Injections should be given in areas where the patient will not be exposed to pressure e.g. not close to waistband or belt and not close to the ribs.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.
4.4 Special warnings and precautions for use
Effect on QT/QTc interval
Long-term androgen deprivation therapy may prolong the QT interval. In the confirmatory study comparing Degarelix acetate to leuprorelin periodic (monthly) electrocardiograms (ECGs) were performed; both therapies showed QT/QTc intervals exceeding 450 msec in approximately 20% of the patients, and 500 msec in 1% and 2% of the degarelix and leuprorelin patients, respectively (see section 5.1).
Degarelix acetate has not been studied in patients with a history of a corrected QT interval over 450 msec, in patients with a history of or risk factors for torsades de pointes and in patients receiving concomitant medicinal products that might prolong the QT interval. Therefore, in such patients, the benefit/risk ratio of Degarelix acetate must be thoroughly appraised (see sections 4.5 and 4.8).
A thorough QT study showed that there was no intrinsic effect of degarelix on QT/QTc interval (see section 4.8).
Patients with known or suspected hepatic disorder have not been included in long-term clinical trials with degarelix. Mild, transient increases in ALT and AST have been seen, these were not accompanied by a rise in bilirubin or clinical symptoms. Monitoring of liver function in patients with known or suspected hepatic disorder is advised during treatment. The pharmacokinetics of degarelix has been investigated after single intravenous administration in subjects with mild to moderate hepatic impairment (see section 5.2).
Degarelix has not been studied in patients with severe renal impairment and caution is therefore warranted.
Degarelix has not been studied in patients with a history of severe untreated asthma, anaphylactic reactions or severe urticaria or angioedema.
Changes in bone density
Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with a GnRH agonist. It can be anticipated that long periods of testosterone suppression in men will have effects on bone density. Bone density has not been measured during treatment with degarelix.
A reduction in glucose tolerance has been observed in men who have had orchiectomy or who have been treated with a GnRH agonist. Development or aggravation of diabetes may occur; therefore, diabetic patients may require more frequent monitoring of blood glucose when receiving androgen deprivation therapy. The effect of degarelix on insulin and glucose levels has not been studied.
Cardiovascular disease such as stroke and myocardial infarction has been reported in the medical literature in patients with androgen deprivation therapy. Therefore, all cardiovascular risk factors should be taken into account.
4.5 Interaction with other medicinal products and other forms of interaction
No formal drug-drug interaction studies have been performed.
Since androgen deprivation treatment may prolong the QTc interval, the concomitant use of degarelix with medicinal products known to prolong the QTc interval or medicinal products able to induce torsades de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated (see section 4.4).
Degarelix is not a substrate for the human CYP450 system and has not been shown to induce or inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 to any great extent?in vitro. Therefore, clinically significant pharmacokinetic drug-drug interactions in metabolism related to these isoenzymes are unlikely.
4.6 Fertility, pregnancy and lactation
Pregnancy and breast-feeding
There is no relevant indication for use of Degarelix acetate in women.
Degarelix acetate may inhibit male fertility as long as the testosterone is suppressed.
4.7 Effects on ability to drive and use machines
Degarelix acetate has no or negligible influence on the ability to drive and use machines. Fatigue and dizziness are common adverse reactions that might influence the ability to drive and use machines.
4.8 Undesirable effects
Summary of the safety profile
The most commonly observed adverse reactions during degarelix therapy in the confirmatory phase III study (N=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. Transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).
The injection site adverse reactions reported were mainly pain and erythema, reported in 28% and 17% of patients, respectively, less frequently reported were swelling (6%), induration (4%) and nodule (3%). These events occurred primarily with the starting dose whereas during maintenance therapy with the 80 mg dose, the incidence of these events pr 100 injections was: 3 for pain and <1 for erythema, swelling, nodule and induration. The reported events were mostly transient, of mild to moderate intensity and led to very few discontinuations (<1%). Serious injection site reactions were very rarely reported such as injection site infection, injection site abscess or injection site necrosis that could require surgical treatment/drainage.
Tabulated list of adverse reactions
The frequency of undesirable effects listed below is defined using the following convention: Very common (? 1/10); common (? 1/100 to < 1/10); uncommon (? 1/1,000 to < 1/100), rare (? 1/10,000 to <1/1,000) and very rare (<1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Table 1: Frequency of adverse drug reactions reported in 1,259 patients treated for a total of 1781 patient years (phase II and III studies) and from post-marketing reports
|MedDRA System Organ Class (SOC)||Very common||Common||Uncommon||Rare|
|Blood and lymphatic system disorders||Anaemia*||Neutropenic fever|
|Immune system disorders||Hypersensitivity||Anaphylactic reactions|
|Metabolism and nutrition disorders||Weight increase*||Hyperglycemia/Diabetes mellitus, cholesterol increased, weight decreased, appetite decreased, changes in blood calcium|
|Psychiatric disorders||Insomnia||Depression, libido decreased*|
|Nervous system disorders||Dizziness, headache||Mental impairment, hypoaesthesia|
|Eye disorders||Vision blurred|
|Cardiac disorders||Cardiac arrhythmia (incl. atrial fibrillation), palpitations, QT prolongation*(see sections 4.4 and 4.5)||Myocardial infarction, cardiac failure|
|Vascular disorders||Hot flush*||Hypertension, vasovagal reaction (incl. hypotension)|
|Respiratory, thoracic and mediastinal disorders||Dyspnoea|
|Gastrointestinal disorders||Diarrhoea, nausea||Constipation, vomiting, abdominal pain, abdominal discomfort, dry mouth|
|Hepatobiliary disorders||Liver transaminases increased||Bilirubin increased, alkaline phosphatase increased|
|Skin and subcutaneous tissue disorders||Hyperhidrosis (incl. night sweats)* , rash||Urticaria, skin nodule, alopecia, pruritus, erythema|
|Musculoskeletal, connective tissue and bone disorders||Musculoskeletal pain and discomfort||Osteoporosis/osteopenia, arthralgia, muscular weakness, muscle spasms, joint swelling/stiffness||Rhabdomyolysis|
|Renal and urinary disorders||Pollakiuria, micturition urgency, dysuria, nocturia, renal impairment, incontinence|
|Reproductive system and breast disorders||Gynaecomastia*, testicular atrophy*, erectile dysfunction*||Testicular pain, breast pain, pelvic pain, genital irritation, ejaculation failure|
|General disorders and administration site conditions||Injection site adverse reactions||Chills, pyrexia, fatigue*, Influenza-like illness||Malaise, peripheral oedema|
*Known physiological consequence of testosterone suppression
Description of selected adverse reactions
Changes in laboratory parameters
Changes in laboratory values seen during one year of treatment in the confirmatory phase III study (N=409) were in the same range for degarelix and a GnRH-agonist (leuprorelin) used as comparator. Markedly abnormal (>3*ULN) liver transaminase values (ALT, AST and GGT) were seen in 2-6% of patients with normal values prior to treatment, following treatment with both medicinal products. Marked decrease in haematological values, hematocrit (?0.37) and hemoglobin (?115 g/l) were seen in 40% and 13-15%, respectively, of patients with normal values prior to treatment, following treatment with both medicinal products. It is unknown to what extent this decrease in haematological values was caused by the underlying prostate cancer and to what extent it was a consequence of androgen deprivation therapy. Markedly abnormal values of potassium (?5.8 mmol/l), creatinine (?177 ?mol/l) and BUN (?10.7 mmol/l) in patients with normal values prior to treatment, were seen in 6%, 2% and 15% of degarelix treated patients and 3%, 2% and 14% of leuprorelin treated patients, respectively.
Changes in ECG measurements
Changes in ECG measurements seen during one year of treatment in the confirmatory phase III study (N=409) were in the same range for degarelix and a GnRH-agonist (leuprorelin) used as comparator. Three (<1%) out of 409 patients in the degarelix group and four (2%) out of 201 patients in the leuprorelin 7.5 mg group, had a QTcF ? 500 msec. From baseline to end of study the median change in QTcF for degarelix was 12.0 msec and for leuprorelin was 16.7 msec.
The lack of intrinsic effect of degarelix on cardiac repolarisation (QTcF), heart rate, AV conduction, cardiac depolarisation, or T or U wave morphology was confirmed in a thorough QT study in healthy subjects (N=80) receiving an i.v. infusion of degarelix over 60 min, reaching a mean Cmax?of 222 ng/mL, approx. 3-4-fold the Cmax?obtained during prostate cancer treatment.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
There is no clinical experience with the effects of an acute overdose with degarelix. In the event of an overdose the patient should be monitored and appropriate supportive treatment should be given, if considered necessary.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Endocrine therapy, Other hormone antagonists and related agents
Mechanism of action
Degarelix is a selective gonadotrophin releasing-hormone (GnRH) antagonist that competitively and reversibly binds to the pituitary GnRH receptors, thereby rapidly reducing the release of the gonadotrophins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), and thereby reducing the secretion of testosterone (T) by the testes. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that removes the source of androgen. Unlike GnRH agonists, GnRH antagonists do not induce a LH surge with subsequent testosterone surge/tumour stimulation and potential symptomatic flare after the initiation of treatment.
A single dose of 240 mg degarelix, followed by a monthly maintenance dose of 80 mg, rapidly causes a decrease in the concentrations of LH, FSH and subsequently testosterone. The serum concentration of dihydrotestosterone (DHT) decreases in a similar manner to testosterone.
Degarelix is effective in achieving and maintaining testosterone suppression well below medical castration level of 0.5 ng/ml. Maintenance monthly dosing of 80 mg resulted in sustained testosterone suppression in 97% of patients for at least one year. No testosterone microsurges were observed after re-injection during degarelix treatment. Median testosterone levels after one year of treatment were 0.087 ng/ml (interquartile range 0.06-0.15) N=167.
Results of the confirmatory Phase III study
The efficacy and safety of degarelix was evaluated in an open-label, multi-centre, randomised, active comparator controlled, parallel-group study. The study investigated the efficacy and safety of two different degarelix monthly dosing regimens with a starting dose of 240 mg (40 mg/ml) followed by monthly doses subcutaneous administration of 160 mg (40 mg/ml) or 80 mg (20 mg/ml), in comparison to monthly intramuscular administration of 7.5 mg leuprorelin in patients with prostate cancer requiring androgen deprivation therapy. In total 620 patients were randomised to one of the three treatment groups, of which 504 (81%) patients completed the study. In the degarelix 240/80 mg treatment group 41 (20%) patients discontinued the study, as compared to 32 (16%) patients in the leuprorelin group.
Of the 610 patients treated
- 31% had localised prostate cancer
- 29% had locally advanced prostate cancer
- 20% had metastatic prostate cancer
- 7% had an unknown metastatic status
- 13% had previous curative intent surgery or radiation and a rising PSA
Baseline demographics were similar between the arms. The median age was 74 years (range 47 to 98 years). The primary objective was to demonstrate that degarelix is effective with respect to achieving and maintaining testosterone suppression to below 0.5 ng/ml, during 12 months of treatment.
The lowest effective maintenance dose of 80 mg degarelix was chosen.
Attainment of serum testosterone (T) ?0.5 ng/ml
Degarelix acetate is effective in achieving fast testosterone suppression, see Table 2.
Table 2: Percentage of patients attaining T?0.5 ng/ml after start of treatment.
|Time||Degarelix 240/80 mg||Leuprorelin 7.5 mg|
Avoidance of testosterone surge
Surge was defined as testosterone exceeding baseline by ?15% within the first 2 weeks.
None of the degarelix-treated patients experienced a testosterone surge; there was an average decrease of 94% in testosterone at day 3. Most of the leuprorelin-treated patients experienced testosterone surge; there was an average increase of 65% in testosterone at day 3. This difference was statistically significant (p<0.001).
Figure 1: Percentage change in testosterone from baseline by treatment group until day 28 (median with interquartile ranges).
The primary end-point in the study was testosterone suppression rates after one year of treatment with degarelix or leuprorelin. The clinical benefit for degarelix compared to leuprorelin plus anti-androgen in the initial phase of treatment has not been demonstrated.
In a study involving patients with rising PSA after localised therapy (mainly radical prostatectomy and radiation) were administered Degarelix acetate for seven months followed by a seven months monitoring period. The median time to testosterone recovery (>0.5 ng/mL, above castrate level) after discontinuation of treatment was 112 days (counted from start of monitoring period, i.e 28 days after last injection). The median time to testosterone >1.5 ng/mL (above lower limit of normal range) was 168 days.
Successful response in the study was defined as attainment of medical castration at day 28 and maintenance through day 364 where no single testosterone concentration was greater than 0.5 ng/ml.
Table 3: Cumulative probability of testosterone ?0.5 ng/ml from Day 28 to Day 364.
|Degarelix 240/80 mg|
|Leuprorelin 7.5 mg|
|No. of responders||202||194|
* Kaplan Meier estimates within group
Attainment of prostate specific antigen (PSA) reduction
Tumour size was not measured directly during the clinical trial programme, but there was an indirect beneficial tumour response as shown by a 95% reduction after 12 months in median PSA for degarelix.
The median PSA in the study at baseline was:
- for the degarelix 240/80 mg treatment group 19.8 ng/ml (interquartile range: P25 9.4 ng/ml, P75 46.4 ng/ml)
- for the leuprorelin 7.5 mg treatment group 17.4 ng/ml (interquartile range: P25 8.4 ng/ml, P75 56.5 ng/ml)
Figure 2: Percentage change in PSA from baseline by treatment group until day 56 (median with interquartile ranges).
This difference was statistically significant (p<0.001) for the pre-specified analysis at day 14 and day 28.
Prostate specific antigen (PSA) levels are lowered by 64% two weeks after administration of degarelix, 85% after one month, 95% after three months, and remained suppressed (approximately 97%) throughout the one year of treatment.
From day 56 to day 364 there were no significant differences between degarelix and the comparator in the percentage change from baseline.
Effect on prostate volume
Three months therapy with degarelix (240/80 mg dose regimen) resulted in a 37% reduction in prostate volume as measured by trans-rectal ultrasound scan (TRUS) in patients requiring hormonal therapy prior to radiotherapy and in patients who were candidates for medical castration. The prostate volume reduction was similar to that attained with goserelin plus anti-androgen protection.
Effect on QT/QTc intervals
In the confirmatory study comparing Degarelix acetate to leuprorelin periodic electrocardiograms were performed. Both therapies showed QT/QTc intervals exceeding 450 msec in approximately 20% of the patients. From baseline to end of study the median change for Degarelix acetate was 12.0 msec and for leuprorelin it was 16.7 msec.
Anti-degarelix antibody development has been observed in 10% of patients after treatment with Degarelix acetate for one year and 29% of patients after treatment with Degarelix acetate for up to 5.5 years. There is no indication that the efficacy or safety of Degarelix acetate treatment is affected by antibody formation after up to 5.5 years of treatment.
The European Medicines Agency has waived the obligation to submit the results of studies with Degarelix acetate in all subsets of the paediatric population (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties
Following subcutaneous administration of 240 mg degarelix at a concentration of 40 mg/ml to prostate cancer patients in the pivotal study CS21, AUC0-28 days?was 635 (602-668) day*ng/ml, Cmax?was 66.0 (61.0-71.0) ng/ml and occurred at tmax?at 40 (37-42) hours. Mean trough values were approximately 11-12 ng/ml after the starting dose and 11-16 ng/ml after maintenance dosing of 80 mg at a concentration of 20 mg/ml. Cmax?degarelix plasma concentration decreases in a biphasic fashion, with a mean terminal half-life (t?) of 29 days for the maintenance dose. The long half-life after subcutaneous administration is a consequence of a very slow release of degarelix from the depot formed at the injection site(s). The pharmacokinetic behaviour of the medicinal product is influenced by its concentration in the solution for injection. Thus, Cmax?and bioavailability tend to decrease with increasing dose concentration while the half-life is increased. Therefore, no other dose concentrations than the recommended should be used.
The distribution volume in healthy elderly men is approximately 1 l/kg. Plasma protein binding is estimated to be approximately 90%.
Degarelix is subject to common peptidic degradation during the passage of the hepato-biliary system and is mainly excreted as peptide fragments in the faeces. No significant metabolites were detected in plasma samples after subcutaneous administration.?In vitro?studies have shown that degarelix is not a substrate for the human CYP450 system.
In healthy men, approximately 20-30% of a single intravenously administered dose is excreted in the urine, suggesting that 70-80% is excreted via the hepato-biliary system. The clearance of degarelix when administered as single intravenous doses (0.864-49.4 ?g/kg) in healthy elderly men was found to be 35-50 ml/h/kg.
Patients with renal impairment
No pharmacokinetic studies in renally impaired patients have been conducted. Only about 20-30% of a given dose of degarelix is excreted unchanged by the kidneys. A population pharmacokinetics analysis of the data from the confirmatory Phase III study has demonstrated that the clearance of degarelix in patients with mild to moderate renal impairment is reduced by approximately 23%; therefore, dose adjustment in patients with mild or moderate renal impairment is not recommended. Data on patients with severe renal impairment is scarce and caution is therefore warranted in this patient population.
Patients with hepatic impairment
Degarelix has been investigated in a pharmacokinetic study in patients with mild to moderate hepatic impairment. No signs of increased exposure in the hepatically impaired subjects were observed compared to healthy subjects. Dose adjustment is not necessary in patients with mild or moderate hepatic impairment. Patients with severe hepatic dysfunction have not been studied and caution is therefore warranted in this group.
5.3 Preclinical safety data
Animal reproduction studies showed that degarelix caused infertility in male animals. This is due to the pharmacological effect; and the effect was reversible.
In female reproduction toxicity studies degarelix revealed findings expected from the pharmacological properties. It caused a dosage dependent prolongation of the time to mating and to pregnancy, a reduced number of?corpora lutea, and an increase in the number of pre- and post-implantation losses, abortions, early embryo/foetal deaths, premature deliveries and in the duration of parturition.
Preclinical studies on safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential revealed no special hazard for humans. Both?in vitro?and?in vivo?studies showed no signs of QT prolongation.
No target organ toxicity was observed from acute, subacute and chronic toxicity studies in rats and monkeys following subcutaneous administration of degarelix. Drug-related local irritation was noted in animals when degarelix was administered subcutaneously in high doses.
6.1 List of excipients
Water for injections
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
Chemical and physical in-use stability has been demonstrated for 2 hours at 25?C. From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
For storage conditions of the reconstituted medicinal product, see section 6.3.
6.5 Nature and contents of container
Glass (type I) vial with bromobutyl rubber stopper and aluminium flip-off seal containing 120 mg powder for solution for injection
Pre-filled glass (type I) syringe with elastomer plunger stopper, tip cap and line-marking at 3 ml containing 3 ml solvent
Injection needle (25G 0.5 x 25 mm)
Pack-size of 2 trays containing 2 powder vials, 2 solvent pre-filled syringes, 2 plunger rods, 2 vial adapters and 2 needles
6.6 Special precautions for disposal and other handling
The instructions for reconstitution must be followed carefully.
Administration of other concentrations is not recommended because the gel depot formation is influenced by the concentration. The reconstituted solution should be a clear liquid, free of undissolved matter.
- THE VIALS SHOULD NOT BE SHAKEN
The pack contains two vials of powder and two pre-filled syringes with solvent that must be prepared for subcutaneous injection. Hence, the procedure described below need to be repeated a second time.
No special requirements for disposal.
7. Manufactured in India By:
TAJ PHARMACEUTICALS LIMITED
Survey No.188/1 to 189/1,190/1 to 4,
Daman- 396210 (INDIA)
Degarelix acetate powder and solvent for solution for injection IP 80mg Taj Pharma
Package leaflet: Information for the patient
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
- What Degarelix acetate is and what it is used for
- What you need to know before you take Degarelix acetate
- How to take Degarelix acetate
- Possible side effects
- How to store Degarelix acetate
- Contents of the pack and other information
1 WHAT DEGARELIX ACETATE IS AND WHAT IT IS USED FOR
Degarelix Acetate powder and solvent for solution for injection contains degarelix.
Degarelix is a synthetic hormone blocker used in the treatment of prostate cancer in adult male patients. Degarelix mimics a natural hormone (gonadotrophin-releasing hormone, GnRH) and directly blocks its effects. By doing so, degarelix immediately reduces the level of the male hormone testosterone that stimulates the prostate cancer.
2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE DEGARELIX ACETATE
Do not take Degarelix acetate
– if you are allergic to Degarelix acetate or any of the other ingredients of this medicine (listed in Section 6).
Warnings and Precautions:
Please tell your doctor if you have any of the following:
– Any cardiovascular conditions or heart rhythm problems (arrythmia), or are being treated with medicines for this condition. The risk of heart rhythm problems may be increased when using Degarelix.
– Diabetes mellitus. Worsening or onset of diabetes may occur. If you have diabetes, you may have to measure blood glucose more frequently.
– Liver disease. Liver function may need to be monito red.
– Kidney disease. Use of Degarelix has not been investigated in patients with severe kidney disease.
– Osteoporosis or any condition that affects the strength of your bones. Reduced level of testosterone may cause a reduction in bone calcium (thinning of bones).
– Severe hypersensitivity. Use of Degarelix has not been investigated in patients with severe hypersensitivity reactions.
Children and Adolescents:
Do not give this medicine to children or adolescent.
Other medicines and Degarelix acetate
Degarelix might interfere with some medicines used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol) or other medicines which can have an effect on heart rhythm (e.g. methadone (used for pain relief and part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics).
Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Driving and using machines
Tiredness and dizziness are common side effects that may impair your ability to drive and use machines. These side effects may be due to the treatment or effects resulting from underlying disease.
3 HOW TO TAKE DEGARELIX ACETATE
This medicine is usually injected by a nurse or doctor.
The recommended starting dose is two consecutive injections of 120 mg. After that, you will receive a monthly 80 mg injection. The injected liquid forms a gel from which degarelix is released over a period of one month.
Degarelix may be injected under the skin (subcutaneously) only. Degarelix must not be given into a blood vessels (inravenously). Precautions must be taken to avoid accidental injection into a vein. The site of injection is likely to vary within the abdominal region.
If you forget to use Degarelix
If you believe your monthly dose of Degarelix has been forgotten, please talk to your doctor.
If you have any further questions on the use of this medicine, ask your doctor.
4 POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them.
A very serious allergic reaction to this medicine is rare. Seek medical advice straight away if you develop a seve re rash, itching or shortness of breath or difficulty breathing. These could be symptoms of a severe allergic reaction.
Very common (may affect more than 1 in 10 people)
Hot flushes, injection site pain and redness. Side effects at the injection site are most common with the starting dose and less common with the maintenance dose.
Common (may affect up to 1 in 10 people)
– Injection site swelling, node and hardness
– chills, fever or influenza ? like illness after the injection.
– trouble sleeping, tiredness, dizziness, headache
– increased weight, nausea, diarrhea, elevated levels of some liver enzymes
– excessive sweating (including night sweats), rash
– musculoskeletal pain and discomfort
– reduced size of testicals, breast swelling, impotence
Uncommon (may affect up to 1 in 100 people)
– loss of sexual desire, testicular pain, pelvic pain, ejaculation faliur, genital irritation, breast pain
– depression, mental impairment
– skin redness, loss of hair, skin nodule, numbness
– allergic reactions, hives, itching
– decreased appetite, constipation, vomiting, dry mouth, abdominal pain and discomfort, increased blood sugar, increased cholesterol, decreased weight
– High blood pressure, change in heart rhythm, change in ECG, feeling of abnormal heart beat.
– blurred vision
-discomfort at injection including decreased blood pressure and heart rate
Rare (may affect up to 1 in 1000 people)
– febrile neutropenia (very low number of white blood cell in combination with fever), heart attack, heart failure.
– unexplained muscular pain or cramps, tenderness, or weakness. The muscle problems can be serious, including muscle breakdown resulting in kidney damage.
Very rare (may affect up to 1 in 10,000 people)
– injection site infection, abscess and necrosis.
Reporting of side effects
If you get any of the side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.
5 HOW TO STORE DEGARELIX ACETATE
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vials, syringes and outer packaging. The expiry date refers to the last day of the month.
This medicine does not require any special storage conditions.
This medicine is stable for 2 hours at 25?C.
Due to the risk of microbial contamination, this medicine should be used immediately. If not used immediately, the use of this medicine is the responsibility of the user.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6 CONTENTS OF THE PACK AND OTHER INFORMATION
What Degarelix acetate contains
The active substance is Degarelix acetate.
a) Each vial contains 80 mg degarelix IP (as acetate).
After reconstitution 1 ml of the reconstituted solution contains 20 mg degarelix.
– The other ingredients of the powder is mannitol.
– The solvent is water for injection.
Contents of the pack
Degarelix is a powder and solvent for solution for injection. The powder is white to off white. The solvent is a clear, colourless solution.
Pack-size of 2 trays containing: 2 vials with powder containing 120 mg of degarelix and 2 pre-filled syringes with 3 ml of solvent. 2 plunger rods, 2 vial adapters and 2 injection needles
7. Manufactured in India By:
TAJ PHARMACEUTICALS LIMITED
at SURVEY NO. 188/1, 190/1TO 4, ATHIYAWAD , DABHEL,
DAMAN- 396210 (INDIA)